SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Monogram Biosciences, Inc. (Nasdaq:MGRM) announced that it expects to report revenues of approximately $62 million for the year ended December 31, 2008, an increase of 44% over the prior year. The company established 2009 revenue guidance of between $66 million and $70 million based on expected growth which, in conjunction with reduction in costs, should achieve cash flow breakeven by the fourth quarter of 2009.
